Cleveland Biolabs Inc. (CBLI) Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
11/18/2009 10:00:14 AM
More...
|
Cleveland Biolabs Inc. (CBLI) to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
10/20/2009 10:53:14 AM
More...
|
Cleveland Biolabs Inc. (CBLI) to Present at 8th Annual BIO Investor Forum
10/19/2009 10:57:48 AM
More...
|
Department of Defense Increases Ongoing Contract With Cleveland Biolabs Inc. (CBLI) for Developmental Studies Related to Protectan CBLB502
10/6/2009 10:50:30 AM
More...
|
Rodman & Renshaw Initiates Analyst Coverage of Cleveland Biolabs Inc. (CBLI)
10/5/2009 2:40:53 PM
More...
|
Armed Forces Radiobiology Research Institute (AFRRI) and Cleveland Biolabs Inc. (CBLI) Awarded Grant From Department of Defense to Study Radioprotective Effects of Protectan CBLB600 Series
9/30/2009 10:57:27 AM
More...
|
Cleveland Biolabs Inc. (CBLI) Awarded $5.3 Million Grand Opportunities Grant From National Institutes of Health (NIH) for Protectan CBLB502 Research in Mitigation of Radiation Damage of GI Tract
9/29/2009 10:36:56 AM
More...
|
Cleveland Biolabs Inc. (CBLI) Receives $2.3 Million Addition to $13.3 Million Contract With Biomedical Advanced Research and Development Authority (BARDA) to Develop Radiation Countermeasure Protectan CBLB502
9/24/2009 10:53:59 AM
More...
|
National Institute of Allergy And Infectious Diseases (NIAID) Awards Cleveland Biolabs Inc. (CBLI) Additional Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage
9/22/2009 11:52:11 AM
More...
|
Cleveland Biolabs Inc. (CBLI) to Present at Maxim Group Growth Conference
9/21/2009 11:18:03 AM
More...
|
|